



14-16  
November  
2024

## 22<sup>ND</sup> CONVENTION OF INVESTIGATORS IN CYSTIC FIBROSIS

XXII CONVENTION D'AUTUNNO  
DEI RICERCATORI IN FIBROSI CISTICA

CENTRO  
CONGRESSI  
CAMERA DI  
COMMERCIO  
VERONA

## PROGRAM



*Fondazione per la Ricerca  
sulla Fibrosi Cistica - ETS  
italian cystic fibrosis research foundation*

Piazzale Stefani 1 | c/o Azienda Ospedaliera Universitaria Integrata | 37126 Verona  
Codice fiscale 93100600233 | [fondazione.ricercafc@aovr.veneto.it](mailto:fondazione.ricercafc@aovr.veneto.it) | Tel 045 812 3438  
[fibrosicisticaricerca.it](http://fibrosicisticaricerca.it)

## Thursday, 14 November 2024

	09:30 - 10:30	Registration and poster display
	10:30 - 11:20	Welcome and greetings <b>Matteo Marzotto</b> ( <i>President FFC Ricerca</i> ) <b>Gianna Puppo Fornaro</b> ( <i>President LIFC Lega Italiana Fibrosi Cistica</i> ) <b>Francesco Blasi</b> ( <i>President SIFC Società Italiana Fibrosi Cistica</i> ) <b>Callisto Marco Bravi</b> ( <i>Director AOUI Verona</i> ) <b>Carlo Castellani</b> ( <i>Scientific director FFC Ricerca</i> ) <b>Cecilia Cascone</b> ( <i>Representative Consultation group FFC Ricerca</i> )
	11:20 - 11:30	<b>Introduction of 22<sup>nd</sup> FFC Ricerca Convention</b> <b>Carlo Castellani</b> ( <i>Scientific director FFC Ricerca</i> )
<b>SESSION 1</b>	11:30 - 13:05	<b>FFC STRATEGIC PROJECTS AND RESEARCH FACILITIES</b> <i>Chair:</i> Nicoletta Pedemonte, Carlo Castellani
		<ol style="list-style-type: none"><li>1. <b>Paola Barraja, Luis J.V. Galietta</b> (Molecules 3.0) New generation of pharmacological modulators to rescue mutant CFTR protein (15')</li><li>2. <b>Anna Cereseto, Sven Even Borgos, Luis J.V. Galietta, Sheref Mansy, Serena Zacchigna</b> (GenDel-CF) - <i>speaker Sjoerd Hak</i> Tackling gene delivery in lungs for the treatment of cystic fibrosis (15')</li><li>3. <b>Maria Cristina Lucanto, Cesare Braggion, Cristina Cigana, Nicoletta Pedemonte</b> (Kaftrio in the real life) Efficacy and safety of Kaftrio in real life: an observational multicenter Italian clinical study (10')</li><li>4. <b>Alessandra Bragonzi</b> (CFaCore) FFC Ricerca Research facilities: The cystic fibrosis animal core (10')</li><li>5. <b>Valeria Capurro</b> (SCP) FFC Ricerca Research facilities: The primary cultures service (10')</li><li>6. <b>Roberto Buzzetti</b> (CFDB) FFC Ricerca Research facilities: The cystic fibrosis database (10')</li></ol>
	12:40 - 13:05	Discussion
	13:05 - 14:30	Lunch
<b>SESSION 2</b>	14:30 - 16:15	<b>ORPHAN MUTATIONS AND NEW THERAPEUTIC APPROACHES</b> <i>Chair:</i> Nicoletta Pedemonte, Maria Cristina Lucanto
		<ol style="list-style-type: none"><li>7. <b>Massimo Aureli, Anna Tamanini</b> (FFC#1/2022) A lipid-based therapeutic approach to rescue F508del-CFTR and CFTR with orphan mutations and implications in bacterial infections in cystic fibrosis (10')</li><li>8. <b>Emilio Hirsch</b> (FFC#3/2022) Rescuing rare CFTR mutants with a PI3K<math>\gamma</math> mimetic peptide (20')</li><li>9. <b>Giulia Maule</b> (GMSG#1/2022) Development of CRISPR-Cas delivery system for genome editing applications in cystic fibrosis (10')</li><li>10. <b>Riccardo Percudani, Gianfranco Pasut, Rosaria Casciaro</b> (FFC#14/2022) Actin-resistant acidic DNase for the treatment of CF pulmonary symptoms (20')</li><li>11. <b>Maria Luisa Mangoni, Arianna Venturini, Mattia Mori</b> (FFC#4/2022) Esculetin-derived peptides as novel therapeutic agents with antimicrobial and CFTR potentiator activities to address cystic fibrosis lung disease (20')</li></ol>
	15:50 - 16:15	Discussion

16:15 - 16:40  
**SESSION 3**

## FLASH PRESENTATION 1: 2024 NEW PROJECTS

*Chair: Ermanno Rizzi*

12. **Giovanni Marzaro, Tamas Hegedus, Gergely L. Lukacs** (FFC#1/2024)  
Development of new potentiators active on (ultra)rare mutants of CFTR (3')
13. **Mauro Salvi** (FFC#3/2024)  
Promoting correct folding to enhance F508del-CFTR rescue induced by correctors (3')
14. **Giovanni Bertoni, Silvia Ferrara** (FFC#5/2024)  
Targeting bacterial small RNA to develop non-traditional therapeutic options against *Pseudomonas aeruginosa* (3')
15. **Sandra Gemma, Arianna Pomilio** (FFC#7/2024)  
Targeting quorum sensing to fight *Pseudomonas aeruginosa* infections (3')
16. **Santiago Ramon-Garcia** (FFC#9/2024) - speaker *Lara Muñoz Muñoz*  
Understanding the contribution of Kaftrio to antimicrobial therapies against nontuberculous mycobacteria in cystic fibrosis (3')
17. **Antonio Recchiuti** (FFC#13/2024)  
Unraveling proresolving effects of CFTR modulators on lung inflammation and infection (3')
18. **Martina Rossitto, Marco Artini** (FFC#15/2024)  
Analysis of the evolution of virulence factors and antimicrobial resistance of *Pseudomonas aeruginosa* in people with cystic fibrosis (3')

Discussion at poster session

16:40 - 18:00	Coffee Break & Poster session
18:00 - 18:30 <b>KEYNOTE SPEECH</b>	<b>How clinical and <i>in vitro</i> data can synergize to facilitate access to modulators in people with cystic fibrosis and orphan mutations</b> <b>Pierre-Régis Burgel (30')</b>

08:30 - 09:50  
**SESSION 4**

**EXPERIMENTAL MODELS AND CFTR BASIC DEFECTS**

*Chair: Valeria Capurro, Giuseppe Magazzù*

**19. Roberto Plebani (GMSG#1/2023)**

Developing a new respiratory 3D model as an innovative strategy to study the inflammation pathology in cystic fibrosis (10')

**20. Marco Cafora (GMRF#1/2023)**

*Ex vivo* pig lung as a new model to study the efficacy of phage therapy against *Pseudomonas aeruginosa* infection in cystic fibrosis (10')

**21. Carlos M. Farinha, Valeria Tomati (FFC#2/2023)**

Exploring the cellular pathways to promote rescue of mutant CFTR protein in cystic fibrosis (10')

**22. Alessandra Bragonzi, Federica Ungaro, Valeria Daccò (FFC#5/2023)**

Beyond the lung: the gut's role in the pathology of cystic fibrosis (10')

**23. Luis J. V. Galietta (FFC#9/2022)**

Effect of inflammatory stimuli on airway epithelium ion transport in cystic fibrosis (20')

9:30 - 9:50

Discussion

9:50 - 10:55  
**SESSION 5**

**BIOLOGICAL EFFECTS OF KAFTRIO**

*Chair: Luis J.V. Galietta, Giuseppe Magazzù*

**24. Andrea Armirotti, Rosaria Bassi (FFC#1/2023)**

Investigation of Kaftrio secondary effects on sphingolipid synthesis (20')

**25. Renata Bocciardi (FFC#3/2023)**

Understanding the mechanisms behind the variable efficacy of CFTR modulators on the N1303K mutation on human primary nasal epithelial cells (10')

**26. Cristina Cigana, Daniela Girelli, Ersilia Vita Fiscarelli (FFC#16/2021)**

Linking elexacaftor/tezacaftor/ivacaftor to infections in cystic fibrosis lung disease (20')

10:40 - 10:55

Discussion

10:55 - 11:20

Coffee Break

11:20 - 12:25  
**SESSION 6**

**PHAGE THERAPY**

*Chair: Alessandra Bragonzi, Carlo Castellani*

**27. Anna Silvia Pistocchi (FFC#12/2022)**

Evaluation of phage interactions with host immune system in models of cystic fibrosis: one step toward phage therapy application (20')

**28. Federica Briani (FFC#16/2023)**

Facing resistance to therapeutic phages observed in *Pseudomonas aeruginosa* isolates from people with cystic fibrosis (10')

**29. Loris Rizzello, Giulia Degiacomi (FFC#11/2023) - speaker Anna Griego**

Resolving *Mycobacterium abscessus* infections with a phages-inspired therapy (20')

12:10 - 12:25

Discussion

30. **Lucilla Nobbio, Andrea Armirotti** (FFC#2/2024)  
 Investigating the safety of elexacaftor/tezacaftor/ivacaftor (ETI) exposure during pregnancy and early development (3')
31. **Onofrio Laselva, Valeria Capurro, Enza Montemitro** (FFC#4/2024)  
 A personalized repurposing approach based on antinflammatory/antioxidant treatment to increase the efficacy of CFTR modulators (3')
32. **Mariagrazia Di Luca, Laura Rindi, Andrea Moscatelli** (FFC#6/2024)  
 Development of phage therapy for treating *Mycobacterium abscessus* lung infections in people with cystic fibrosis (3')
33. **Annalisa Guaragna, Eliana De Gregorio** (FFC#8/2024)  
 A combined therapy against *Pseudomonas aeruginosa-Staphylococcus aureus* co-infections in cystic fibrosis (3')
34. **Stefano Sabatini, Laura Rindi** (FFC#10/2024)  
 Phenotypic medicinal chemistry approaches to identify new anti-*Mycobacterium abscessus* agents (3')
35. **Alberto Battezzati, Federico Alghisi, Stefano Costa** (FFC#14/2024)  
 Long-term clinical outcomes of insulin secretory defects and effects of CFTR modulators (3')
36. **Daniela Guidone** (GMRF#1/2024)  
 Airway surface as a battleground against bacteria (3')
37. **Michele Genovese** (GMSG#1/2024)  
 Alternative therapeutic target to restore the mucociliary clearance in CF (3')

Discussion at poster session

12:50

Group photo at Auditorium

13:10 - 15:10

Lunch & Poster session

15:10 - 16:40  
**SESSION 8**

## **UNDERSTANDING INFLAMMATION**

*Chair: Giulio Cabrini, Natalia Cirilli*

38. **Domenico Mattoscio** (FFC#11/2022, FFC#12/2024)  
 Targeting platelet activation with pro-resolving mediators: an innovative strategy to dampen lung inflammation in cystic fibrosis (23')
39. **Mario Romano, Mauro Perretti** (FFC#15/2023)  
 Melanocortins to control cystic fibrosis airway inflammation (10')
40. **Moira Paroni, Clelia Peano** (FFC#14/2023)  
 Identification of molecular mechanisms which underpin the activation of pathogenic pulmonary Th1/17 cells in cystic fibrosis (10')
41. **Ilaria Lampronti, Adriana Chilin** (FFC#10/2022, FFC#11/2024)  
 Towards the development of GY-971a as anti-inflammatory drug in cystic fibrosis (23')

16:16 - 16:40

Discussion

16:40 - 17:05

Coffee Break

17:05 - 17:35  
**KEYNOTE SPEECH**

**Inflammation research priorities in the changing scenario of cystic fibrosis**  
 Marcus A. Mall (30')

20:00

SOCIAL DINNER

at Palazzo Verità Poeta - Vicoletto San Silvestro 6, Verona

## Saturday, 16 November 2024

9:30 - 11:25  
SESSION 9

### NEW STRATEGIES AGAINST PSEUDOMONAS AND ASPERGILLUS

Chair: Paola Bruni, Sonia Volpi

42. **Barbara Citterio, Massimiliano Lucidi** (FFC#7/2023) - speaker Gianmarco Mangiaterra  
Evaluation of cefiderocol activity against *Pseudomonas aeruginosa* in cystic fibrosis lung infections (10')
43. **Giordano Rampioni** (FFC#10/2023)  
Drug repurposing to inhibit *Pseudomonas aeruginosa* adaptation to the CF lung environment (20')
44. **Silvia Buroni, Antonio Coluccia** (FFC#6/2023)  
Using a Virtual Screening approach to find new drugs against *Pseudomonas aeruginosa* and *Staphylococcus aureus* (10')
45. **Marco Sette, Mattia Falconi, Marco Rinaldo Oggioni** (FFC#13/2023)  
Building simple molecules containing regions of *Pseudomonas aeruginosa* to stimulate the immune system against this pathogen (10')
46. **Eugenio Notomista, Ivana D'Angelo** (FFC#8/2023)  
Inhalable nanoparticles delivering peptidomimetic/antibiotic combinations for local treatment of CF lung infections (10')
47. **Andrea Battistoni, Luigi Scipione** (FFC#4/2023)  
A Trojan horse strategy to improve the treatment of *Pseudomonas aeruginosa* lung infections (20')
48. **Teresa Zelante** (FFC#15/2022)  
Study on anti-fungal immunoglobulins, as a potential diagnostic biomarker and therapeutic values for allergic bronchopulmonary aspergillosis in children with cystic fibrosis (10')

11:00 - 11:25 Discussion

11:25 - 11:55 Coffee Break

11:55 - 13:25  
SESSION 10

### FIGHTING MYCOBACTERIA INFECTIONS

Chair: Alessandra Bragonzi, Natalia Cirilli

49. **Nicola Ivan Lorè, Lisa Cariani** (FFC#7/2022)  
Genomic and phenotypic characterization of *Mycobacterium abscessus* and detection of host biomarkers to define mycobacterial infection in cystic fibrosis (10')
50. **Laurent Robert Chiarelli, Fiorella Meneghetti, Sonia Covaceuszach** (FFC#5/2022)  
Nontuberculous mycobacteria in cystic fibrosis: scouting molecules against *Mycobacterium abscessus* iron acquisition pathways (20')
51. **Maurizio Fraziano, Daniela Maria Cirillo** (FFC#13/2022)  
Fighting *Mycobacterium abscessus* infections by a novel combination therapy with liposome/Kaftrio/antibiotic (20')
52. **Edoardo Scarpa, Daniela Maria Cirillo** (FFC#12/2023)  
Fostering pathogen host-mediated clearance to neutralize *Mycobacterium abscessus* infection (10')
53. **Maria Rosalia Pasca, Fabio Saliu, Riccardo Manganelli** (FFC#9/2023)  
Evaluation of the efficacy of the "VOMG" new antibiotic against *Mycobacterium abscessus* (10')

13:05 - 13:25	Discussion
13:25 - 13:35	Closing remarks
13:35 - 14:00	Poster detachment

## Notes

With the patronage of



AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA  
VERONA



With the support of



CAMERA DI COMMERCIO  
INDUSTRIA ARTIGIANATO  
AGRICOLTURA VERONA

**Tamberi ha affrontato nella sua carriera tante difficoltà, non arrendendosi mai.**

**E noi, con lui al nostro fianco, facciamo lo stesso.**



Emma, ragazza con la fibrosi cistica e Gianmarco Tamberi, campione olimpico di salto in alto



**Fondazione per la Ricerca  
sulla Fibrosi Cistica - ETS**  
[fibrosicisticaricerca.it](http://fibrosicisticaricerca.it)

**Sostieni la ricerca per i malati ancora senza cura.**

**A NATALE SCEGLI I DONI SOLIDALI FFC RICERCA**  
[su fibrosicisticaricerca.it](http://fibrosicisticaricerca.it)